BILLS-117hr3537ih.pdf

2021 later than 120 days 1986 5-year later than one year 2026 1965 1ST SESSION H. R. 3537 MAY 25, 2021 later than 6 months

the ‘‘Accelerating Access

PO 00000 Frm 00010 PO 00000 Frm 00006 PO 00000 Frm 00011 Fmt

3537 IH the United States of America Connecticut Illinois Texas Nebraska California Missouri Pennsylvania New Jersey Georgia Wisconsin

lish

DSK79L0C42PROD SEC Health and Human Services the Federal Food, Drug U.S.C. the Food and Drug Administration ALS Federal MULLIN THE HOUSE OF REPRESENTATIVES Partnership for Neurodegenerative the Small Business Act RUPPERSBERGER Food and Drug Administration the Food and Drug Administra- the Public Health Service Act Critical Therapies Congress non-Federal HHS PUBLIC-PRIVATE PARTNERSHIP House of Representa- the Food and Drug Adminis- MER FUNDS.—A Department of Health and Human Services the Food and Drug Ad- 21 the Committee on Energy VERT Food, Drug Human Services the National Institutes of Health Senate APPROPRIATIONS the Internal Revenue Code

DEUTCH RODNEY DAVIS DEAN BURCHETT GARCIA MEEKS THOMPSON PANETTA ESPAILLAT RUSH BROWNLEY LAMALFA PAYNE MOORE NORTON DEGETTE MENG BAIRD TURNER TIMMONS HICE CROW AMODEI VAN LARSON CICILLINE MORELLE KIM LIEU LEE CARBAJAL RUTHERFORD FLEISCHMANN YOUNG KEATING MALINOWSKI CARTER SUOZZI KIRKPATRICK BRENDAN F. BOYLE SCHWEIKERT LEVIN SWALWELL GROTHMAN QUIGLEY NAPOLITANO FITZPATRICK SCANLON AXNE JACKSON LEE

amyotrophic amyotrophic lateral lateral sclerosis expanded access sclerosis clinical trial lateral cure amyotrophic investigational drug clinical participating trial cosmetic act drug cosmetic